News

HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical…

2 years ago

Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference

DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization…

2 years ago

Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022

BOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy…

2 years ago

Iterum Therapeutics Reports First Quarter 2022 Financial Results

-General Alignment with FDA on Key Aspects of Design of Proposed Additional Clinical Trial- -Cash Runway into 2024- DUBLIN, Ireland and…

2 years ago

ProMIS Neurosciences Announces First Quarter 2022 Results

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or…

2 years ago

Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update

FDA approval for EPSOLAY® (benzoyl peroxide, cream, 5%) represents Sol-Gel’s second approved product within less than a year; EPSOLAY is…

2 years ago

Humacyte First Quarter 2022 Financial Results and Business Update

-- Human Acellular Vessels™ (HAVs™) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries…

2 years ago

ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or…

2 years ago

FindThisBest Selects Tauri-Gum as The #1 Best Kosher Chewing Gum in the Overall Marketplace

Tauriga Sciences, Inc. Top 3 Finishers - FindThisBest Kosher Chewing Gum ReviewNEW YORK, NY, May 13, 2022 (GLOBE NEWSWIRE) --…

2 years ago

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

Topline readout of Phase 2 AML trial Group 2 active disease anticipated in Q2 2022 Company plans to file INDs…

2 years ago